The Effect of Multimodal Treatment of Rectal Cancer on Circulating Tumor Cells: A Prospective, Observational Study

ConditionRectal Cancer Patients

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorThe Institute of Molecular and Translational Medicine, Czech Republic

About this trial

The prospective study will focus on patients undergoing multimodal treatment for rectal cancer. The main objective of the study will be to monitor changes in circulating tumor cells (CTCs) in the peripheral blood of patients during multimodal treatment. For each patient enrolled in the study, peripheral blood samples will be collected at specified time intervals to determine the presence and quantity of CTCs.

The CTCs levels will be compared among rectal cancer patients with neoadjuvant chemoradiotherapy and without neoadjuvant chemotherapy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Rectal cancer patients

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

150 Participants

are grouped into 2 trial groups

Group A: Rectal cancer patients with neoadjuvant chemoradiotherapy

Group B: Rectal cancer patients without neoadjuvant chemoradiotherapy

Trial outcomes

Primary outcomes

Levels of circulating tumor cells in peripheral blood

The levels of circulating tumor cells will be measured in rectal cancer patients

Time frame

The levels of circulating tumor cells will be measured in 5 time points: before neoadjuvant chemoradiotherapy, in 3. week of chemoradioterapy, before surgery, one week after surgery and one month after surgery.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The Institute of Molecular and Translational Medicine, Czech Republic

Lead sponsor

Source ClinicalTrials.gov

Apply now